Clinical trials
Completed Phase 1 trials in Austria
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
194 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2000 | 1 |
| 2002 | 1 |
| 2003 | 1 |
| 2005 | 4 |
| 2006 | 9 |
| 2007 | 9 |
| 2008 | 8 |
| 2009 | 9 |
| 2010 | 12 |
| 2011 | 15 |
| 2012 | 11 |
| 2013 | 9 |
| 2014 | 13 |
| 2015 | 9 |
| 2016 | 14 |
| 2017 | 8 |
| 2018 | 5 |
| 2019 | 7 |
| 2020 | 11 |
| 2021 | 10 |
| 2022 | 8 |
| 2023 | 6 |
| 2024 | 4 |
| 2025 | 3 |
| 2026 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 194 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Novo Nordisk A/S | 31 |
| Medical University of Vienna | 18 |
| Affiris AG | 10 |
| Novartis Pharmaceuticals | 9 |
| European Organisation for Research and Treatment of Cancer - EORTC | 7 |
| Amgen | 6 |
| Bayer | 6 |
| Medical University of Graz | 4 |
| Arecor Limited | 3 |
| Baxalta now part of Shire | 3 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Diabetes Mellitus, Type 1 | 24 |
| Diabetes Mellitus | 18 |
| Diabetes Mellitus, Type 2 | 11 |
| Alzheimer Disease | 7 |
| Neoplasms | 6 |
| Pain | 5 |
| Parkinson Disease | 5 |
| Hemophilia A | 4 |
| Lung Neoplasms | 4 |
| Colitis, Ulcerative | 3 |
Trials
Showing 1 to 25 of 194. Each trial links to its page on Pharma Observatory.
94 more trials match. See them on Pharma Observatory
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.